Lung cancers can use two different mechanisms to evade KRAS-inhibiting drugs
About 25% of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, the FDA has approved two KRAS inhibitors to treat patients with KRAS mutations. While these drugs can work well initially, tumors almost always develop resistance to them.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Decadelong study finds smoking worsens sickle cell retinopathy
United Kingdom
-
Remote-control in the cortex—how distant synapses are equipped for change
United Kingdom
-
Childhood family environments impact midlife cardiovascular and cognitive health
United Kingdom
-
New Gobi Desert Fossil Rewrites a Chapter of Mammal Evolution
United Kingdom
-
Wearable stroke rehabilitation device gives patients the upper hand
United Kingdom
-
Your voice may reveal how fast and how well you're aging
United Kingdom
-
How parenting profiles are associated with children's behavioral and emotional problems
United Kingdom
-
Newly uncovered enzyme mechanism could help target drug-resistant breast cancer
United Kingdom